SCHEMBL6840358

SCHEMBL6840358

CC(=O)OCc1nc(C)cs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 7/20 0.40
MAPT P10636 7/20 0.40
NPC1 O15118 6/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
HSP90AA1 P07900 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
APEX1 P27695 1/20 0.39
RECQL P46063 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12126178 0.83 RAB9A (0.41) RAB9AMAPTNPC1L3MBTL1CASP3
SCHEMBL12126031 0.81 NPC1 (0.59) CYP1A2CYP2C19RAB9AMAPTNPC1
SCHEMBL5637413 0.81 CYP1A2 (0.45) CYP1A2CYP2C19RAB9AMAPTNPC1
SCHEMBL13593122 0.79 CYP1A2 (0.44) CYP1A2CYP2C19RAB9AMAPTNPC1
SCHEMBL743224 0.79 MAPT (0.47) CYP1A2CYP2C19RAB9AMAPTNPC1
SCHEMBL12126033 0.79 RAB9A (0.49) RAB9AMAPTNPC1L3MBTL1CASP3
SCHEMBL2115567 0.79 MAPT (0.64) CYP1A2CYP2C19RAB9AMAPTNPC1
SCHEMBL5639344 0.78 CYP1A2 (0.43) CYP1A2CYP2C19RAB9AMAPTNPC1
SCHEMBL11705928 0.78 TDP1 (0.50) RAB9AMAPTNPC1TDP1PKM
SCHEMBL12128092 0.78 L3MBTL1 (0.53) CYP1A2CYP2C19RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653141-B2 HIV protease inhibiting compounds ABBVIE INC. (US) 2014-02-18 US disclosed
US-20130023463-A1 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2013-01-24 US disclosed
US-8193227-B2 HIV protease inhibiting compounds ABBOTT LABORATORIES (US) 2012-06-05 US disclosed
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 US disclosed
US-20110003827-A1 HIV protease inhibiting compounds ABBVIE INC. 2011-01-06 US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003827-A1 HIV protease inhibiting compounds SERPINB1, HPN, DNPEP CYP1A2 2459/4885CYP2C19 1394/4885RAB9A 2012/4885
US-20130023463-A1 HIV PROTEASE INHIBITING COMPOUNDS SERPINB1, HPN, DNPEP CYP1A2 2459/4885CYP2C19 1394/4885RAB9A 2012/4885
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 CYP1A2 12/4885CYP2C19 14/4885RAB9A 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.